# OnCo record ziftomenib (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/ziftomenib/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "ziftomenib" ;
  schema:name "Ziftomenib"@en ;
  schema:description "Ziftomenib is the second menin inhibitor for leukaemia, approved in November 2025 as a once-daily pill for relapsed NPM1-mutated AML."@en ;
  schema:url <https://onco.cc/drugs/ziftomenib/> ;
  schema:dateModified "2026-09-07"^^xsd:date ;
  schema:citation <https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Ziftomenib> ;
  onco:status "approved" ;
  onco:modality "Small-molecule menin inhibitor" ;
  schema:alternateName "Komzifti" ;
  onco:approval "US 2025: Relapsed/refractory NPM1-mutated AML with no satisfactory alternative" ;
  onco:related <https://onco.cc/drugs/revumenib/>, <https://onco.cc/biomarkers/npm1-mutation/> ;
  onco:cancers <https://onco.cc/cancers/aml/>, <https://onco.cc/cancers/all-leukemia/>, <https://onco.cc/cancers/aml-npm1-kmt2a/> ;
  onco:technologies <https://onco.cc/technologies/epigenetic-drugs/> ;
  onco:targets <https://onco.cc/targets/menin/>, <https://onco.cc/targets/npm1/>, <https://onco.cc/targets/kmt2a/> ;
  onco:companies <https://onco.cc/companies/kura-oncology/> ;
  onco:terms <https://onco.cc/terms/differentiation-syndrome/> ;
  onco:trials <https://onco.cc/trials/komet-001/>, <https://onco.cc/trials/nct07007312/>, <https://onco.cc/trials/nct07623616/> .